{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for phenyl root_codes_MANUFACTURER\ PRODUCT\ INFORMATION in MANUFACTURER PRODUCT INFORMATION (approximate match)
Showing 1 - 5 of 5 results
Status:
Investigational
Source:
NCT00160862: Phase 1 Interventional Completed Healthy
(2003)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00090532: Phase 1/Phase 2 Interventional Terminated Age-Related Macular Degeneration
(2004)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Pfizer developed AG-013958, also known as AG-13958 for treatment of age-related macular degeneration (AMD). As a VEGFR tyrosine kinase inhibitor, AG13958 was targeted to FLT/TYK receptor inhibition.
